Advertisement
Table 3 Final main effects linear model of the association between baseline explanatory variables and day 7 lumefantrine concentration in ng/mL (433 patients).
| Variable | Coefficient | 95%CI | p-value | p-value (trend) | |
|---|---|---|---|---|---|
| lower | upper | ||||
| referred from hospital OPD (vs. from outlying clinics) | -198.3 | -316.9 | -63.1 | 0.005 | |
| unsupervised treatment | -463.3 | -536.8 | -381.0 | <0.0001 | |
| age | |||||
| ≥15 years | [reference] | <0.0001 | |||
| 5–14 years | -54.6 | -233.3 | 158.4 | 0.591 | |
| <5 years | -357.9 | -483.8 | -208.6 | <0.0001 | |
| lumefantrine dose (mg/Kg) | |||||
| ≥80 | [reference] | 0.375 | |||
| 65–79 | -168.6 | -319.3 | 9.1 | 0.062 | |
| 50–64 | -187.5 | -348.4 | 5.1 | 0.056 | |
| <50 | -36.1 | -287.0 | 286.8 | 0.806 | |
| gametocytaemic at inclusion | 395.2 | 89.5 | 775.7 | 0.009 | |
| history of dizziness at inclusion | -284.4 | -414.9 | -131.1 | 0.001 | |
| constant | |||||
| adjusted R2: 0.219 | |||||
| p-value for goodness of fit: <0.0001 | |||||
